Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Ionis Pharmaceuticals, Inc.”

202 pharma patents match "Ionis Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 202
Index total 30,257
Page 1 / 9

Quick answer

This filtered view shows 202 pharmaceutical patents matching "Ionis Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

202 results for “Ionis Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12409188

    Modulators of HSD17B13 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  2. US 12410430

    Modulating apolipoprotein (A) expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  3. US 12350285

    Compounds and methods for reducing ATXN3 expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  4. US 12343357

    Compositions and methods for modulating MECP2 expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  5. US 12297431

    Modulation of huntingtin expression

    Ionis Pharmaceuticals, Inc. · Granted May 13, 2025 · Expires May 8, 2045

    granted
  6. US 12291709

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  7. US 12281305

    Compounds and methods for reducing prion expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  8. US 12275940

    Conjugated antisense compounds and their use

    Ionis Pharmaceuticals, Inc. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  9. US 12241067

    Compounds and methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  10. US 12227746

    Compounds and methods for modulating SCN2A

    Ionis Pharmaceuticals, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  11. US 12215321

    Modulators of diacyglycerol acyltransferase 2 (DGAT2)

    Ionis Pharmaceuticals, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  12. US 12188020

    Methods for reducing Ataxin-2 expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  13. US 12180479

    Compounds and methods for modulating ATXN1

    Ionis Pharmaceuticals, Inc. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  14. US 12152244

    Selective antisense compounds and uses thereof

    Ionis Pharmaceuticals, Inc. · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted
  15. US 12115225

    GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof

    Ionis Pharmaceuticals, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  16. US 12110491

    Selective reduction of allelic variants

    Ionis Pharmaceuticals, Inc. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  17. US 12043831

    Modulation of alpha synuclein expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  18. US 12042510

    Modulators of IRF4 expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  19. US 12030910

    Compounds and methods for the modulation of proteins

    Ionis Pharmaceuticals, Inc. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  20. US 12018261

    Compounds and methods for modulating factor XII

    Ionis Pharmaceuticals, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  21. US 11981897

    Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression

    Ionis Pharmaceuticals, Inc. · Granted May 14, 2024 · Expires May 9, 2044

    granted
  22. US 11959080

    Methods and compositions for inhibiting PMP22 expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  23. US 11926825

    Compounds and methods for reducing ATXN2 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  24. US 11926830

    Modulators of Complement Factor B

    Ionis Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted